卵巢癌药物市场规模预计将从 2024 年的 24.3 亿美元增长到 2031 年的 42.3 亿美元;预计 2024-2031 年期间市场复合年增长率为 7.1%。
市场洞察和分析师观点:
卵巢癌发病率的上升推动了 卵巢癌药物市场的增长。然而,由于不良反应而导致的产品召回阻碍了市场的增长。
增长动力:
卵巢癌发病率上升推动对治疗方案的需求
卵巢癌是女性第七大常见癌症,也是第三大常见妇科恶性肿瘤,仅次于宫颈癌和子宫内膜癌。根据世界卵巢癌联盟的报告,每年有32.4万名女性被诊断患有卵巢癌,20.7万名女性死于该病。此外,由于缺乏可用于早期发现卵巢癌的公共卫生筛查项目,大多数卵巢癌患者在确诊时已处于晚期(局部晚期或转移性)。因此,卵巢癌发病率的上升推动了对有效治疗方案的需求。对于新诊断的晚期卵巢癌患者,一线治疗方案是减瘤手术联合铂类化疗,是标准治疗方案。此外,已获批准的PARP抑制剂、奥拉帕尼、鲁卡帕尼和尼拉帕尼等治疗方案是治疗新诊断卵巢癌的突破性方案。 PARP抑制剂在晚期卵巢癌治疗中的应用也已成为改善临床疗效的有效选择。对于新诊断的卵巢癌患者,在接受第一、二、三次铂类化疗获得完全缓解(CR)后,这些抑制剂可提供长期疗效和无进展生存期(PFS)。
您可以免费定制任何报告,包括本报告的部分内容、国家级分析、Excel 数据包,以及为初创企业和大学提供优惠和折扣
卵巢癌药物市场:

- 获取此报告的顶级关键市场趋势。此免费样品将包括数据分析,从市场趋势到估计和预测。
报告细分和范围:
卵巢癌药物市场分析已通过考虑以下部分进行:类型、药物类别和分销渠道。
节段分析:
按类型划分,市场分为上皮性卵巢癌、生殖细胞卵巢癌和间质肿瘤。2022年,上皮性卵巢癌占据了卵巢癌药物市场的最大份额;预计该领域在预测期内的复合年增长率将达到8.2%。根据英国癌症研究中心的报告,上皮性卵巢癌是最常见的卵巢癌类型。例如,每100个卵巢肿瘤中,近90个(90%)是上皮性肿瘤。对于患有侵袭性晚期卵巢癌的患者,市场上可用的治疗方案有限。2022年11月,美国食品药品监督管理局 (FDA) 宣布批准由Elahere ImmunoGen, Inc.生产的“mirvetuximab soravtansine-gynx”,用于治疗患有上皮性卵巢癌的成年患者。该候选药物用于治疗上皮性卵巢癌的医生推荐剂量为6毫克/千克,每三周静脉输注一次。2024年1月,FDA宣布批准“RC88”的快速通道认定(FTD),这是一种靶向间皮素的抗体-药物偶联物(ADC),用于治疗复发性上皮性卵巢癌患者。因此,药物批准数量的不断增长正在推动上皮性卵巢癌领域卵巢癌药物市场的发展。CAGR of 8.2% during the forecast period. According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, nearly 90 out of 100 tumors of the ovary (90%) are epithelial tumors. Patients with aggressive, late-stage ovarian cancer have limited treatment options available in the market. In November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The physician-recommended dose of this drug candidate for epithelial ovarian cancer treatment is 6 mg/kg, administered once every three weeks as an IV infusion. In January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting
卵巢癌药物市场趋势
联合药物治疗
多家医学研究机构正在开发用于治疗卵巢癌的新型联合用药。2023年9月,皇家马斯登医院的研究人员宣布了一种新的药物联合疗法,该疗法已被证明对晚期卵巢癌患者有效。研究人员测试了联合用药疗法对低级别浆液性卵巢癌(LGSOC)的疗效。LGSOC是一种罕见的卵巢癌,对治疗的反应率较低。RAMP-201临床试验将avutometinib与defactinib联合使用,以探究其对LGSOC患者的协同治疗效果。中期临床试验结果显示,45%接受该药物联合治疗的患者肿瘤显著缩小。如此令人满意的临床效果几乎是曲美替尼(trametinib)的两倍,曲美替尼是目前在英国上市的靶向治疗药物,其反应率仅为26%。2024年1月,美国食品药品监督管理局(FDA)宣布批准SH-105联合用药,用于治疗乳腺癌和卵巢癌患者。因此,联合药物疗法正在成为新的趋势,并可能在未来几年推动卵巢癌药物市场的增长。
区域分析:
卵巢癌药物市场报告涵盖北美、欧洲、亚太地区、南美和中美以及中东和非洲。2022年,北美占据了卵巢癌药物市场的最大份额。该地区市场的增长得益于顶级公司推出的产品数量不断增加以及主要市场参与者的参与。美国是北美市场最大的贡献者。女性卵巢癌发病率的上升迫使公司和监管机构分别在该地区开发和批准创新药物。此外,合同临床研究组织 (CRO) 数量的增加也有利于北美卵巢癌药物市场的增长。
卵巢癌药物市场区域洞察
Insight Partners 的分析师已详尽阐述了预测期内影响卵巢癌药物市场的区域趋势和因素。本节还讨论了北美、欧洲、亚太地区、中东和非洲以及南美和中美洲的卵巢癌药物市场细分和地域分布。

- 获取卵巢癌药物市场的区域特定数据
卵巢癌药物市场报告范围
报告属性 | 细节 |
---|---|
2024年的市场规模 | 24.3亿 |
2031年的市场规模 | 42.3亿 |
全球复合年增长率(2024-2031) | 7.1% |
史料 | 2021-2023 |
预测期 | 2025-2031 |
涵盖的领域 | 按类型
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
卵巢癌药物市场参与者密度:了解其对业务动态的影响
卵巢癌药物市场正在快速增长,这得益于终端用户需求的不断增长,而这些需求的驱动因素包括消费者偏好的转变、技术进步以及对产品益处的认知度的提升。随着需求的增长,企业正在扩展产品线,不断创新以满足消费者需求,并抓住新兴趋势,从而进一步推动市场增长。
市场参与者密度是指特定市场或行业内企业或公司的分布情况。它表明特定市场空间内竞争对手(市场参与者)的数量相对于其规模或总市值而言。
在卵巢癌药物市场运营的主要公司有:
- 艾莉·莉莉
- 阿斯利康
- 葛兰素史克
- 齐拉布
- 免疫原
- 基因科技(罗氏)
免责声明:以上列出的公司没有按照任何特定顺序排列。

- 了解卵巢癌药物市场主要参与者概况
行业发展和未来机遇:
卵巢癌药物市场预测可以帮助该市场的利益相关者规划其增长战略。以下列出了市场领先企业的一些战略发展:
- 2022年11月,ImmunoGen公司获得美国食品药品监督管理局(FDA)批准ELAHERE(mirvetuximab soravtansine-gynx),用于治疗铂类耐药性上皮性卵巢癌成年患者。ELAHERE专门用于治疗FRα阳性铂类耐药性卵巢癌患者。由于治疗方案有限且现有疗法临床疗效不佳,此类卵巢癌的治疗极具挑战性。
竞争格局和重点公司:
这份卵巢癌药物市场报告中重点介绍的知名公司包括礼来(Elli Lilly)、阿斯利康(AstraZeneca)、葛兰素史克(GSK)、Zielab、ImmunoGen(艾伯维)、GeneTech(罗氏)、Vivesto、Allarity Therapeutics, Inc.、Aeterna Zentaris 和绿叶制药(Luye Pharma)。这些公司专注于开发新技术、升级现有产品并拓展市场,以满足全球日益增长的消费者需求。
- 历史分析(2 年)、基准年、预测(7 年)及复合年增长率
- PEST 和 SWOT 分析
- 市场规模价值/数量 - 全球、区域、国家
- 行业和竞争格局
- Excel 数据集



Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
常见问题
Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2024.
The CAGR value of the ovarian cancer drugs market during the forecasted period of 2025-2031 is 7.1%.
The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.
Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.
Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.
The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2024.
The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2024.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Ovarian Cancer Drugs Market
- Elli Lilly
- AstraZeneca
- GSK
- Zielab
- ImmunoGen
- GeneTech (Roche)
- Vivesto
- Allarity Therapeutics, Inc.
- Aeterna Zentaris
- Luye Pharma
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.